药物 (2023年第83卷第5-6期)
一、April 2023 Volume 83 Issue 5(2023年4月第83卷第5期)
https://link.springer.com/journal/40265/volumes-and-issues/83-5
Leading Article(社评)
1. 慢性乙型肝炎的新兴疗法及其功能性治疗的潜力
(Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure)
作者:Ming-Ling Chang, Yun-Fan Liaw (Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan)
Review Article(综述文章)
1. RRx-001:NLRP3激活和慢性炎症的晚期多指征抑制剂综述
(A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation) 作者:Nanthini Jayabalan (Faculty of Medicine, UQ Centre for Clinical Research, The University of Queensland, Australia)
Systematic Review(系统综述)
1. 黄连素治疗成人血脂异常的总体疗效和性别特异性:随机安慰剂对照试验的系统评价和Meta分析
(Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials )
作者:Joseph E. Blais (School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China)
Original Research Article(原创性研究文章)
1. 阿司匹林预防早期和重度子痫前期复发:一项基于真实人群的研究
(Aspirin for the Prevention of Early and Severe Pre-Eclampsia Recurrence: A Real-World Population-Based Study)
作者:Grégory Lailler (Université Paris Est, France)
AdisInsight Report(AdisInsight报告)
1. 特普利珠单抗:首次获批
(Teplizumab: First Approval)
作者:Susan J. Keam (Springer Nature, New Zealand)
2. 贝沙格列净:首次获批
(Bexagliflozin: First Approval)
作者:Sheridan M. Hoy (Springer Nature, New Zealand)
3. 优必妥单抗:首次批准
(Ublituximab: First Approval)
作者:Arnold Lee (Springer Nature, New Zealand)
二、April 2023 Volume 83 Issue 6(2023年4月第83卷第6期)
https://link.springer.com/journal/40265/volumes-and-issues/83-6
Current Opinion(现行意见)
1. 将减肥与血糖控制作为新诊断的2型糖尿病的主要治疗目标:为什么选择两者都可以?
(Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?)
作者:Theocharis Koufakis (Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Greece)
Leading Article(社评)
1. 靶向小分子治疗系统性红斑狼疮:正在研制中的药物
(Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline)
作者:Chi Chiu Mok (Department of Medicine, Tuen Mun Hospital, China)
Therapy in Practice(实践治疗)
1. 表现为轴性症状的银屑病关节炎患者的治疗
(Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms )
作者:Denis Poddubnyy (Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité-Universitätsmedizin Berlin, Germany)
Review Article(综述文章)
1. 单克隆抗体治疗在原发性膜性肾病中的应用进展
(Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy)
作者:Le Deng, Gaosi Xu (Department of Nephrology, The Second Affiliated Hospital of Nanchang University, China)
Systematic Review(系统综述)
1. 营养疗法在男性因素不孕症治疗中的有效性:系统综述和网络Meta分析
(Effectiveness of Nutritional Therapies in Male Factor Infertility Treatment: A Systematic Review and Network Meta-analysis)
作者:Mohammad Ishraq Zafar (Institute of Reproductive Health/Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, China)
AdisInsight Report(AdisInsight报告)
1. Pirtobrutinib:首次获批
(Pirtobrutinib: First Approval)
作者:Susan J. Keam (Springer Nature, New Zealand)
2. 艾拉司群:首次获批
(Elacestrant: First Approval)
作者:Sheridan M. Hoy (Springer Nature, New Zealand)
3. Sparsentan:首次批准
(Sparsentan: First Approval)
作者:Yahiya Y. Syed (Springer Nature, New Zealand)
- 12024药学监护浦江论坛邀请函(第二轮)2024-09-05 17:57:10
- 2要点梳理 | 器官移植免疫抑制治疗药物监测(广州)研讨会2024-09-05 09:02:33
- 3国际TOP10药学期刊文章信息 (2024年7月)2024-09-02 16:10:38
- 4国际TOP10医学期刊药物治疗信息 (2024年6月)2024-08-09 13:52:01
- 5治疗药物监测杂志文章信息(2024年第46卷第3期)2024-08-05 09:47:51
- 6国际TOP10药学期刊文章信息 (2024年6月)2024-07-23 11:52:44
- 7器官移植免疫抑制治疗药物监测(北京)研讨会圆满落幕2024-07-16 12:07:39
- 8治疗药物监测杂志文章信息(2024年第46卷第2期)2024-07-15 14:44:30
- 9国际TOP10药学期刊文章信息 (2024年5月)2024-06-28 15:14:35
- 10新书推荐 |《治疗药物监测质量控制与人员培训手册》2024-06-27 12:47:06